Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Aug. 31, 2026 /P

Kazia's first 6 TNBC patients all achieved clinical benefits. These early results make paxalisib a m

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-foc

SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Com

Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-foc

SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Com

Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated

Kazia Therapeutics is rated Strong Buy, driven by best-in-class potential for paxalisib and a discou

Canaccord Genuity analyst John Newman initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with

Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing thera

Clinically relevant perioperative studies demonstrate elimination of residual disease and prevention

BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy ratin

Lake Street initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces

Mr. Levine brings more than two decades of experience across investment banking, executive and finan

SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Ther

Based on continued encouraging safety, tolerability and clinical activity data observed to date, pla

Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tol

SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology

SYDNEY, Australia, April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clini

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metas

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metas

HC Wainwright & Co. analyst Sean Lee reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy a

Kazia Therapeutics shared clinical update on Phase 1b study of paxalisib for late-stage metastatic T

Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study

SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical u

SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chie

Novogen Limited (NASDAQ: KZIA - Get Free Report) was the target of a large drop in short interest du

Novogen (NASDAQ: KZIA - Get Free Report) and Opthea (NASDAQ: OPT - Get Free Report) are both small-c

Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-

HC Wainwright & Co. analyst Sean Lee maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy an

First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions

First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions

Kazia Therapeutics Limited (NASDAQ: KZIA) announced a private placement of approximately $50 million

Kazia announced a private placement of $50 million in equity securities. Proceeds will fund clinical

Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, today announ

SYDNEY , Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused

LOW: 6% | Lowe's shares are trading higher despite mixed Q3 financial results. The company raise